NKGEN Biotech

Focus: NKGEN Biotech is a public-stage biotechnology company focused on autologous and allogenic Natural Killer (NK) cell therapies for oncology, neurodegenerative disease, and inflammatory conditions. The company operates as a clinical-stage player with a diversified pipeline but no marketed products generating revenue.

Gene Therapy Cell Therapy

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NKGEN Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow NKGEN Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SNK02

Pathologically Confirmed Cancer Refractory to Conventional Therapy

PHASE_1

Clinical Trials (1)

NCT05990920Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Phase 1

Help build intelligence for NKGEN Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering NK cell therapy platform with multiple clinical programs across high-value disease areas (Alzheimer's, head & neck cancer, solid tumors, psoriasis) offering exposure to cutting-edge cell therapy science
Public company status provides equity upside potential and greater organizational stability than early-stage private biotech, with established governance and disclosure frameworks
Diversified pipeline with 8 active trials across Phase 1 and Phase 2 creates multiple value inflection points and reduces single-program clinical risk

Watch Out For

Zero active job openings at time of data capture signals no current hiring momentum, limiting immediate entry points and suggesting possible resource constraints or hiring freeze
Pre-revenue stage with no disclosed financials creates uncertainty around cash runway, burn rate, and ability to fund pipeline through critical clinical milestones without dilutive financing
Early-stage pipeline (no Phase 3 programs) means 5-7+ years to potential NDA/approval; long duration to first commercial inflection and associated execution and market risk

Generated by Claude from NKGEN Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SNK01

Refractory Cancer

PHASE_1

Clinical Trials (1)

NCT03941262Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Phase 1

SNK01

Alzheimer Disease

PHASE_1

Clinical Trials (1)

NCT04678453Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Phase 1